New dye technique may improve liver cancer surgery outcomes
NCT ID NCT07295275
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two ways of injecting a dye (ICG) during laparoscopic liver surgery for people with liver cancer. The dye helps surgeons see tumor edges more clearly. Researchers want to know if injecting the dye into an artery works better than the usual method of injecting it into the portal vein. The goal is to remove tumors more completely and reduce the chance of cancer coming back. About 200 adults aged 18-80 with liver cancer are being recruited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Indocyanine Green (ICG) dye injected into an artery or portal vein during surgery
What this could lead to
If it works, this could point toward a safer, more effective surgical technique for removing liver tumors, potentially reducing cancer recurrence.
What could go wrong
This is a mid-stage study with 200 participants, so results may not apply to all patients. The dye injection routes carry risks like bleeding or infection, and the surgery itself is complex.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tsinghua Changgung Hospital
RECRUITINGBeijing, Beijing Municipality, China
Contact Phone: •••-•••-••••
-
West China Hospital
RECRUITINGChengdu, Sichuan, 610041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Xuzhou Central Hospital
RECRUITINGXuzhou, Jiangsu, China
Contact Phone: •••-•••-••••